Martin Delaney Collaboratories for HIV Cure Research

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for the Martin Delaney Collaboratories (MDCs) for HIV Cure Research. The goal of the MDC program is to develop strategies to control viral replication without the need for lifelong antiretroviral therapy, with an ultimate goal of completely eradicating HIV reservoirs from the individual. The program will also address the unique needs of children living with HIV. The MDC program will accelerate HIV cure research by fostering strategic collaborations among academic institutions, scientists in government, the private sector, and community stakeholders. The program provides economies of scale by leveraging shared reagents, research resources, and specialized technologies in support of basic, translational, and clinical research. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.